{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-302302","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.472576+00:00","generated_at":"2026-06-21T06:10:36.387472+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cogent Biosciences reports 89% ORR in TKI-naive AdvSM patients from Phase 2 APEX trial","bullets":["89% ORR in TKI-naïve patients; 73% ORR in all evaluable patients (median 27-week follow-up).","First confirmed CR at 20 weeks; 77% with ≥2 cycles had complete clearance of bone marrow mast cell aggregates.","No related cognitive effects or intracranial bleeding; favorable safety profile with mostly Grade 1/2 events.","Median age 69 years; subtypes: ASM (3), SM-AHN (12), MCL (1); 3 had prior avapritinib/midostaurin.","Plans to present initial PEAK lead-in data H1 2023 and SUMMIT data H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-302302","json":"https://secwatch.observer/filing/0001193125-22-302302.json","markdown":"https://secwatch.observer/filing/0001193125-22-302302.md","text":"https://secwatch.observer/filing/0001193125-22-302302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312522302302/0001193125-22-302302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312522302302/d421322d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:10:36.387472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}